Doxapram

Overview

A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)

Indication

For use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease.

Associated Conditions

Anesthetic complication pulmonary
Acute Hypercapnia
Drug-induced Respiratory depression
Postoperative respiratory depression

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial	2025/06/15	NCT07022704	N/A	Recruiting	Cairo University
Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension	2024/09/05	NCT06585163	Phase 1	Not yet recruiting	Quivive Pharma, Inc.
Doxapram Therapy in Preterm Infants (DOXA Trial)	2020/06/12	NCT04430790	Phase 3	Recruiting	Erasmus Medical Center
The Effect of Doxapram Versus Theophylline on Diaphragmatic Function	2019/03/28	NCT03894189	Not Applicable	UNKNOWN	Beni-Suef University
The Effect and Mechanism of Respiratory Stimulant Doxapram on Facilitating Emergence	2016/06/30	NCT02820025	Not Applicable	UNKNOWN	General Hospital of Ningxia Medical University
Doxapram as an Additive to Propofol Sedation in Sedation for ERCP	2014/06/24	NCT02171910	Phase 4	Completed	Helsinki University Central Hospital
Aminophylline and Cognitive Function After Sevoflurane Anaesthesia	2009/12/01	NCT01022151	Phase 2	Completed	King Faisal University
Staccato Alprazolam in Panic Attack	2007/05/23	NCT00477451	Phase 2	Completed	Alexza Pharmaceuticals, Inc.
Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants	2006/10/19	NCT00389909	Phase 4	Completed	Jean Michel Hascoet

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Dopram	Hikma Pharmaceuticals USA Inc.	0641-6018	INTRAVENOUS	20 mg in 1 mL	2/19/2021
DOXAPRAM HYDROCHLORIDE	HF Acquisition Co LLC, DBA HealthFirst	51662-1404	INTRAVENOUS	20 mg in 1 mL	2/22/2020

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
DOPRAM INJ 20MG/ML	ayerst laboratories	01914103	Liquid - Intravenous	20 MG / ML	12/31/1992
DOPRAM INJECTABLE LIQ 20MG/ML	wyeth-ayerst canada inc.	02041839	Liquid - Intravenous	20 MG / ML	12/31/1994

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access